Skip to main content

Table 2 Cochrane risk of bias summary of included RCTs

From: Impact of preoperative 5α-reductase inhibitors on perioperative blood loss in patients with benign prostatic hyperplasia: a meta-analysis of randomized controlled trials

Study

Random Sequence Generation

Allocation Concealment

Blinding of participants and personnel

Blinding of outcome assessment

Incomplete outcome data

Selective outcome reporting

Other sources of bias

Sandfeldt 2001 [10]

Unclear risk

low risk

low risk

low risk

low risk

low risk

low risk

HäggstrÖm 2002 [13]

Unclear risk

Unclear risk

high risk

high risk

low risk

low risk

low risk

Donohue 2002 [8]

Unclear risk

Unclear risk

low risk

Unclear risk

low risk

low risk

low risk

Liu 2003 [5]

Unclear risk

Unclear risk

high risk

high risk

high risk

low risk

low risk

Li 2004 [6]

Unclear risk

Unclear risk

high risk

high risk

high risk

low risk

low risk

Özdal 2005 [4]

Unclear risk

Unclear risk

low risk

Unclear risk

low risk

low risk

low risk

Lund 2005 [19]

low risk

low risk

Unclear risk

Unclear risk

low risk

low risk

low risk

Boccon 2005 [16]

Unclear risk

low risk

low risk

low risk

low risk

low risk

low risk

Lekas 2006 [7]

low risk

Unclear risk

high risk

high risk

low risk

low risk

low risk

Hahn 2007 [20]

Unclear risk

low risk

low risk

low risk

low risk

low risk

low risk

Memis 2008 [11]

Unclear risk

Unclear risk

high risk

high risk

low risk

low risk

low risk

Berardinis 2008 [9]

Unclear risk

low risk

low risk

low risk

low risk

low risk

low risk

Tuncel 2009 [21]

Unclear risk

Unclear risk

high risk

high risk

high risk

low risk

low risk

Kravchick 2009 [17]

high risk

low risk

high risk

high risk

high risk

low risk

low risk

He 2012

Unclear risk

Unclear risk

high risk

high risk

high risk

low risk

low risk

Pastore 2013

low risk

Unclear risk

low risk

Unclear risk

low risk

low risk

low risk

Liu 2013 [14]

Unclear risk

Unclear risk

high risk

high risk

low risk

low risk

low risk

  1. 5ARI 5α-reductase inhibitors, Fin finasteride, Dut dutasteride, MVD microvessel density, VEGF vascular endothelial growth factor, RR relative risk, MD mean difference, CI confidence interval
  2. afavors control